Adagio Medical Holdings, Inc. (ADGM): Nasdaq/NYSE listing notice — Adagio Medical receives Nasdaq notice for bid price < $1; 180-day cure period until Dec 9, 2026

Adagio Medical Holdings, Inc.

Notice from Nasdaq on June 12, 2026 for non-compliance with Listing Rule 5550(a)(2) (min $1 bid).
Stock continues trading on Nasdaq Capital Market during 180-day cure period ending Dec 9, 2026.
To regain compliance, bid price must close at or above $1 for at least 10 consecutive trading days.
Second 180-day period may be available if necessary; delisting possible if non-compliance persists.
Company considering options including reverse stock split to meet bid price requirement.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Adagio Medical Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 12, 2026, Adagio Medical Holdings, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days (the “ Minimum Bid Price Requirement ”). The notification does not impact the listing of the Company’s common stock on The Nasdaq Ca

View on SEC.gov

95 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Adagio Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-073517

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.